Plus Therapeutics Hires HEOR Expert to Boost CNS Cancer Market Access
Event summary
- Plus Therapeutics appointed Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR on April 13, 2026.
- Dr. Goodman brings 20+ years of health economics and market access experience from roles at Pfizer, Gilead, and Moderna.
- He was granted 9,000 shares of equity (4,500 options, 4,500 RSUs) as an inducement to join.
- Will focus on commercial expansion of CNSide Diagnostics and market access for REYOBIQ and CNS oncology pipeline.
The big picture
The hire underscores Plus Therapeutics' focus on strengthening market access for its CNS cancer diagnostics and therapeutics. With increasing scrutiny on healthcare value and reimbursement, Dr. Goodman's expertise in health economics and payer strategy could be pivotal for commercial success. This move aligns with broader industry trends toward value-based healthcare models and payer-centric commercialization approaches.
What we're watching
- Market Access Strategy
- How Dr. Goodman's payer engagement strategies will impact CNSide and REYOBIQ adoption rates.
- Commercial Execution
- Whether Plus can effectively demonstrate clinical and economic value to payers and providers.
- Pipeline Development
- The pace at which Plus advances its broader CNS oncology pipeline with new market access leadership.
Related topics